Mike Hollan

Ketan Mehta provides examples of how he’s developed new therapies that address both regulatory concerns and patient needs.

Dr. Jeremy Levin discusses the importance of relying on scientific fact to make decisions in biotech research.

Reports also claim that Kyle Diamantas will serve as acting head of FDA.

Tris Pharma CEO Ketan Mehta explains how addressing a drug’s impact can improve patient experience.

Ketan Mehta, CEO of Tris Pharma, explains how the company expanded its pipeline over the past two decades.

Radiopharmaceutical logistics is fundamentally different from traditional pharmaceutical supply chains.

Natalie de Graaf, from the API Innovation Center, discusses a recent whitepaper detailing areas where the generic drugs pipeline is under stress.

Charlie Lyon, VP of manufacturing, procurement, and logistics at the API Innovation Center, discusses the complicated web of global manufacturing.

Aradigm Health’s CEO discusses how payers and other entities in the healthcare ecosystem are developing strategies to ensure cell & gene therapy costs don’t prevent patients from accessing them.

Aradigm Health CEO Will Shrank discusses the shift in value-based care models for cell and gene therapies.

Will Shrank, Aradigm Health’s CEO, discusses the importance of transparency in healthcare payments to build trust and reduce waste.

Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.

Innomar’s VP of commercial strategy and innovation discusses the shifting global landscape and building relationships with pharma manufacturers.

Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the importance of meeting the needs of everyone at the table.

Kaida Biopharma’s chair and acting CEO discusses how President Trump’s MFN policies and other regulatory actions are impacting pharma’s ability to invest in new treatments and adjusting international launch strategies.

Dr. Stella Vnook explains how pharma pricing is likely to be impacted by various regulatory actions, such as MFN.

Jessica Lovett, VP of commercial strategy and innovation at Innomar, explains how handling uncertainty comes down to discipline.

Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust strategies in international markets.

Experts convened for a panel discussing how tariffs and MFN policies are impacting drug pricing and what regulatory hurdles they face ahead of the midterms later this year.

Tommy Bramley, SVP of global consulting at Cencora, discusses how broadening acceptance of RWE has a broad impact on launch strategies.

MaxCyte’s CEO explains the various ways CGT is impacted by new technologies and methods of treatment delivery.

Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.

Accurate and reliable data is essential to provide leaders with the right information to power these systems.

Traditional randomized trials are often impractical for treatments in the rare and ultra rare disease space.

Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the pharmaceutical industry.

MaxCyte CEO Maher Masoud discusses how new treatment methods are providing greater control of the therapy’s safety profile.

Enabling highly individualized treatment approaches that align with each patient’s unique physiology, goals, and tolerability, compounding can have a significant impact.

Maher Masoud, CEO of MaxCyte, discusses the need for developers to come together with platforms.

Samsung Bioepis’ SVP and head of US commercial discusses the pricing, regulatory, and broader issues impacting the biosimilars market.